ZMYM4 Antibody

What is ZMYM4 and why is it significant for developmental and cellular research?

ZMYM4 (Zinc finger MYM-type protein 4) is a transcriptional regulator that plays critical roles in developmental processes, particularly in craniofacial development. Research indicates that ZMYM4 regulates the expression of genes in the neural border (NB), neural plate (NP), neural crest (NC), and preplacodal ectoderm (PPE) during embryonic development .

ZMYM4 has been implicated in:

• Regulation of early cranial gene expression

• Neural crest development and migration

• Proper morphology of craniofacial cartilages

• Potential involvement in DNA damage response

Although initially considered as a potential transcriptional cofactor for Six1, research has demonstrated that it does not physically interact with or alter the transcriptional activity of Six1 . ZMYM4 is increasingly studied due to its associations with human disorders including schizophrenia, obesity, sleep disorders, and various cancers .

What are the common applications for ZMYM4 antibodies in research?

ZMYM4 antibodies are utilized in several key research applications:

Selection of the appropriate application depends on your specific research question and experimental design.

How do I select the appropriate ZMYM4 antibody for my specific research needs?

When selecting a ZMYM4 antibody, consider these critical factors:

• Target epitope location: Different antibodies target various regions of ZMYM4 (N-terminal, internal, or C-terminal). For example, some antibodies target the amino acids 1-50 region, while others target AA 144-193 or AA 850-900 . The epitope location affects which isoforms are detected and whether post-translational modifications interfere with antibody binding.

• Host species: Most commercial ZMYM4 antibodies are rabbit-derived polyclonal antibodies , which affects your secondary antibody selection and potential cross-reactivity issues.

• Species reactivity: Verify that the antibody recognizes ZMYM4 from your species of interest. Most ZMYM4 antibodies react with human samples, but cross-reactivity with mouse, rat, and other species varies .

• Validation for specific applications: Ensure the antibody has been validated for your intended application (WB, IP, IHC, etc.).

• Isoform specificity: Some antibodies detect all known isoforms of ZMYM4, while others may be isoform-specific .

What protocol modifications are necessary when using ZMYM4 antibodies for detecting SUMOylated forms?

ZMYM4 is highly SUMOylated, and detecting these modified forms requires specific protocol adjustments:

• Lysis buffer components: Include N-ethylmaleimide (NEM) in your lysis buffer to inhibit SUMO-specific proteases. Research has shown that higher molecular weight forms of ZMYM4 (SUMOylated forms) are stable in the presence of NEM but not in its absence .

• Sample preparation: Direct lysis in SDS-sample buffer better preserves SUMOylated forms compared to NP40-containing buffer .

• Gel electrophoresis conditions: SUMOylated forms of ZMYM4 appear as higher molecular weight bands (above the predicted 167 kDa) and require adequate gel resolution to distinguish these forms.

• Controls: Include samples treated with SUMO protease inhibitors (positive control) and SUMO proteases like SENP1 (negative control) to confirm the identity of SUMOylated bands .

• Blotting technique: Transfer conditions may need optimization for efficient transfer of higher molecular weight proteins.

Research by Werwein et al. demonstrated that ZMYM4 SUMOylation appears to be regulated during the cell cycle, with reduced SUMOylation observed during mitosis following treatment with the kinesin Eg5 inhibitor STLC .

How can I optimize co-immunoprecipitation experiments to study ZMYM4 protein interactions?

For successful co-immunoprecipitation (Co-IP) of ZMYM4 and its binding partners:

• Buffer composition: Use a buffer that preserves protein-protein interactions while effectively lysing cells. For ZMYM4 interactions with B-MYB, standard IP buffers with NP40 detergent have been successful .

• Antibody selection: Choose antibodies that recognize epitopes not involved in protein-protein interactions. For ZMYM4, antibodies targeting the N-terminal or C-terminal regions might be preferable as the central region contains interaction domains .

• Crosslinking considerations: For transient or weak interactions, consider using reversible crosslinking reagents before lysis.

• SUMOylation status: Be aware that NEM (used to preserve SUMOylation) might disrupt ZMYM4 interactions. When studying ZMYM4's interaction with B-MYB, it was observed that in the presence of NEM, the binding was almost completely lost .

• Controls to include:

  • Input sample (pre-IP lysate)

  • IgG control (non-specific antibody of same isotype)

  • Flowthrough samples

  • Reverse Co-IP when possible

• Detection: For analyzing ZMYM4 in Co-IP experiments, Western blotting with antibodies such as mouse anti-αTubulin (DM1A at 1:5,000) as loading control and appropriate secondary antibodies has been effective .

What are the key methodological considerations for using ZMYM4 antibodies in developmental studies?

When studying ZMYM4 in developmental contexts:

• Embryonic tissue processing: For in situ hybridization following ZMYM4 antibody use, careful fixation and processing are essential. Studies examining ZMYM4's role in cranial development used specific fixation protocols for embryonic tissues .

• Knockdown verification: When using morpholinos for ZMYM4 knockdown, verify knockdown efficiency by Western blot, normalizing to αTubulin to determine knockdown efficacy .

• Staging considerations: ZMYM4 expression and function vary during developmental stages. Studies in Xenopus showed different effects at neural plate stages compared to later larval development .

• Domain-specific analysis: In developmental studies, evaluate ZMYM4 expression in specific domains separately. For instance, analysis of neural border, neural plate, neural crest, and preplacodal ectoderm domains revealed domain-specific effects of ZMYM4 knockdown .

• Phenotypic analysis: When assessing developmental phenotypes after ZMYM4 manipulation, quantitative scoring systems (e.g., "increased," "decreased," or "no change" in expression domains) provide consistent evaluation methods .

• Co-staining approaches: For investigating developmental roles, co-staining with markers for specific tissues (e.g., sox9 for neural crest) can help elucidate ZMYM4's function in particular lineages .

How do I interpret multiple bands in Western blots when using ZMYM4 antibodies?

Multiple bands in ZMYM4 Western blots may represent:

• Isoforms: At least three isoforms of ZMYM4 are known to exist . The predicted molecular weight of full-length ZMYM4 is approximately 167 kDa .

• Post-translational modifications: ZMYM4 is highly SUMOylated, leading to higher molecular weight bands. Research has shown that:

  • SUMOylated forms appear as higher molecular weight bands

  • These modified forms are labile in cell extracts unless SUMO protease inhibitors (like NEM) are included

  • Multiple SUMOylation sites may exist, as evidenced by multiple higher molecular weight forms

• Proteolytic fragments: ZMYM4 may undergo proteolytic processing during sample preparation.

For proper interpretation:

• Always include molecular weight markers

• Use positive controls with known ZMYM4 expression

• Consider using truncated recombinant ZMYM4 constructs (e.g., ZMYM4 33-425, 33-1077, 425-1077, 1077-1548) as reference standards

• Compare results with and without SUMO protease inhibitors to identify SUMOylated forms

• Validate with different antibodies targeting distinct epitopes

What are the potential sources of variability in ZMYM4 antibody experiments?

Several factors can contribute to variability in ZMYM4 antibody experiments:

• SUMOylation status: ZMYM4's SUMOylation appears to be regulated during the cell cycle, with reduced SUMOylation in mitosis . This dynamic modification can lead to variable band patterns depending on the cell cycle distribution in your samples.

• Cell type differences: Expression and post-translational modifications of ZMYM4 vary across cell types. For example, studies have shown different effects of ZMYM4 knockdown in HEK293 cells versus HepG2 cells .

• Developmental stage: In developmental studies, ZMYM4 expression and function change during embryogenesis, affecting antibody detection patterns .

• Experimental conditions: Sample preparation methods, particularly lysis conditions, significantly impact ZMYM4 detection. Direct lysis in SDS buffer versus NP40-containing buffers yields different results .

• Antibody specificity: Different antibodies recognize distinct epitopes, which may be affected by protein-protein interactions or post-translational modifications .

• Technical variations: Transfer efficiency, blocking conditions, and incubation times all contribute to variability in signal intensity.

To minimize variability, standardize protocols, include appropriate controls, and consider biological replicates from different experimental conditions.

How can I distinguish between specific and non-specific signals when using ZMYM4 antibodies?

To differentiate specific from non-specific signals:

• Validation controls:

  • Use ZMYM4 knockdown samples as negative controls. For example, translate-blocking morpholinos have been used to verify antibody specificity

  • Include a rescue experiment where ZMYM4 expression is restored in knockdown cells/tissues

  • Compare results from multiple antibodies targeting different ZMYM4 epitopes

• Pre-absorption controls: Pre-incubate the antibody with the immunizing peptide before use. Specific signals should be reduced or eliminated.

• Sample type and preparation:

  • For Western blotting, enriched nuclear fractions may improve specificity as ZMYM4 is primarily nuclear

  • For immunohistochemistry, proper antigen retrieval and blocking are critical

• Pattern analysis:

  • Specific ZMYM4 signals should correlate with known expression patterns

  • In developmental studies, specific signals should be consistent with in situ hybridization data for ZMYM4 mRNA

• Technical considerations:

  • Secondary antibody-only controls to rule out non-specific binding

  • Use of highly cross-adsorbed secondary antibodies to minimize cross-reactivity

• Signal characteristics: Specific signals typically have consistent molecular weights in Western blots or subcellular localization patterns in imaging that align with known ZMYM4 biology.

How can ZMYM4 antibodies be used to investigate its role in the DNA damage response?

ZMYM4 has been implicated in DNA damage response pathways through its interaction with B-MYB. To investigate this role:

• Damage-induced interaction studies:

  • Co-immunoprecipitation experiments have shown that ZMYM4's interaction with B-MYB is stimulated upon induction of DNA damage

  • This interaction involves B-MYB's central domain, where serine residues 306, 307, and 309 are critical for binding

• Phosphorylation analysis:

  • ZMYM4 antibodies can be used in combination with phospho-specific antibodies to study how DNA damage affects phosphorylation of ZMYM4 or its binding partners

  • Immunoprecipitation followed by phospho-specific Western blotting can reveal damage-induced modifications

• SUMOylation dynamics:

  • ZMYM4 is highly SUMOylated, and this modification may change following DNA damage

  • Protocols using NEM to preserve SUMOylation can be combined with DNA damage treatments to study how damage affects ZMYM4 SUMOylation

• Chromatin association:

  • Chromatin immunoprecipitation (ChIP) with ZMYM4 antibodies before and after DNA damage can reveal changes in genomic binding sites

  • Sequential ChIP (re-ChIP) can identify co-occupancy with DNA damage response factors

• Nuclear dynamics:

  • Immunofluorescence with ZMYM4 antibodies can track its redistribution following DNA damage

  • Co-localization with γH2AX or 53BP1 foci can indicate recruitment to damage sites

What approaches can be used to investigate cell cycle-dependent regulation of ZMYM4?

Research has indicated that ZMYM4 may be regulated in a cell cycle-dependent manner, particularly its SUMOylation status. To investigate this:

• Synchronized cell population analysis:

  • Use ZMYM4 antibodies for Western blotting of synchronized cell populations

  • Studies have shown that STLC (S-Trityl-L-cystein) treatment, which arrests cells in mitosis, reduces the higher molecular weight ZMYM4 forms, suggesting cell cycle-dependent SUMOylation

• Flow cytometry approaches:

  • Combine ZMYM4 immunostaining with DNA content analysis to correlate ZMYM4 levels with cell cycle stages

  • Compare with cyclin markers (e.g., cyclin B1 for G2/M) to confirm cell cycle stages

• Live cell imaging:

  • If using fluorescently tagged ZMYM4, validate its behavior with antibody staining of endogenous ZMYM4

  • Track ZMYM4 localization changes throughout the cell cycle

• Protein stability assessment:

  • Cycloheximide chase experiments with ZMYM4 antibody detection can reveal if protein stability changes during the cell cycle

  • Compare half-life across different cell cycle phases

• Post-translational modification analysis:

  • Analyze SUMOylation, phosphorylation, and other modifications across the cell cycle

  • Immunoprecipitation of ZMYM4 followed by modification-specific antibody detection

• Functional studies:

  • Unlike B-MYB knockdown, which causes G2/M arrest and defective cytokinesis in HEK293 cells, ZMYM4 knockdown showed no obvious cell cycle effects in these cells

  • Cell-type specific effects may exist and require targeted investigation

How can ZMYM4 antibodies be used to investigate its role in transcriptional regulation?

To study ZMYM4's function in transcriptional regulation:

• Chromatin immunoprecipitation (ChIP):

  • ZMYM4 antibodies can be used for ChIP to identify genomic binding sites

  • Studies with related proteins like ZMYM2 have employed ChIP-seq to discover binding to transposable elements

  • R method kmeans with the option 'centers = 3' has been used to cluster ChIP-seq peaks into functionally distinct categories

• Transcription factor complex analysis:

  • Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) with ZMYM4 antibodies can identify co-regulatory factors

  • Related ZMYM family member ZMYM2 has been found to interact with transcriptional regulators TRIM28 and ADNP through such approaches

• Reporter assays:

  • Luciferase reporter assays can assess ZMYM4's effect on transcription

  • Prior studies showed that neither ZMYM4 alone nor in combination with Six1 significantly altered luciferase activity from a Six1-responsive reporter

• Gene expression analysis following ZMYM4 manipulation:

  • RNA-seq or qPCR analysis after ZMYM4 knockdown can identify regulated genes

  • Research has shown that ZMYM4 knockdown altered expression of neural border genes, neural plate genes, neural crest genes, and preplacodal ectoderm genes

• Co-occupancy studies:

  • Sequential ChIP can determine if ZMYM4 co-occupies genomic regions with other transcription factors

  • Genome-wide correlation of binding sites with chromatin state marks can reveal activating or repressive functions

• Targeted gene expression studies:

  • In situ hybridization following ZMYM4 manipulation demonstrated effects on specific developmental genes including dlx5, sox9, and tbx1

What methodological approaches are necessary to study ZMYM4 in the context of human disease?

ZMYM4 has been associated with various human diseases including obesity, schizophrenia, sleep disorders, and cancer. To investigate these associations:

• Patient sample analysis:

  • Immunohistochemistry with ZMYM4 antibodies on patient tissues can reveal expression changes

  • ZMYM4 antibodies have been validated for human tonsil tissue at 5 μg/mL concentration

• Genetic variant functional studies:

  • For identified disease-associated variants, create equivalent mutations and analyze effects on:

    • Protein localization (immunofluorescence)

    • Protein-protein interactions (co-immunoprecipitation)

    • SUMOylation status (Western blotting with NEM)

    • Transcriptional effects (reporter assays)

• Cell model systems:

  • Create disease-relevant cellular models (e.g., patient-derived iPSCs)

  • Validate antibody reactivity in these models before proceeding with experiments

• Pathway analysis:

  • Combine ZMYM4 antibody studies with analysis of disease-relevant pathways

  • For cancer studies, correlate with markers of proliferation, apoptosis, or specific oncogenic pathways

• High-throughput approaches:

  • Tissue microarrays with ZMYM4 antibodies can analyze expression across large patient cohorts

  • Correlation with clinical outcomes and other molecular markers

• Therapeutic targeting evaluation:

  • For potential therapeutic development, ZMYM4 antibodies can be used to monitor protein levels following experimental interventions

  • Verification of target engagement in drug development pipelines